Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma (Nasdaq:CNTB) announced that management will join a fireside chat at the H.C.

Rhea-AI Summary

Connect Biopharma (Nasdaq:CNTB) announced that management will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 9:30 a.m. ET.

A live webcast and a replay for about 90 days will be available in the Investors section of the company website.

Argus May 13 session

-8.58% close to close Open Argus

Details

News Market Reaction – CNTB

In the May 13 session, CNTB declined 8.58%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -8.6% in the session following this news. A negative reaction despite this low-impac...

Analysis

The stock moved -8.6% in the session following this news. A negative reaction despite this low-impact conference news fits a pattern where positive clinical updates previously coincided with sharp declines, such as the 15.94% drop on March 30 around data and financing. Market focus may have remained on financing needs and prior losses noted in recent filings, while the conference itself offered limited new information to offset those concerns.

Key Figures

Conference date: May 19, 2026 Presentation time: 9:30 a.m. ET Conference edition: 4th annual +1 more

Conference date

May 19, 2026

H.C. Wainwright 4th Annual BioConnect Investor Conference

Presentation time

9:30 a.m. ET

Scheduled fireside chat at the conference

Conference edition

4th annual

H.C. Wainwright BioConnect Investor Conference

Replay availability

approximately 90 days

Archived webcast on company investor website

Historical Context

5 past events · Latest: Apr 23

5 events

1. Apr 23

   Interim trial update

   24h Move

   -3.1%

   DMC interim analysis kept Phase 2 Seabreeze STAT enrollment and design unchanged.

2. Mar 31

   Earnings and update

   24h Move

   +3.8%

   Full-year 2025 results plus positive rademikibart data and private placement details.

3. Mar 30

   Private placement financing

   24h Move

   -15.9%

   Announced $20.2M private placement of 6,130,000 shares at $3.25 per share.

4. Mar 30

   Phase 3 AD data

   24h Move

   -15.9%

   Phase 3 RADIANT-AD showed high EASI-75 and IGA 0/1 response rates for rademikibart.

5. Mar 30

   Phase 1 IV data

   24h Move

   -15.9%

   Phase 1 IV rademikibart in asthma/COPD showed rapid, durable lung function gains.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4^th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.

The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802

Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Connect Biopharma (CNTB) present at the H.C. Wainwright 4th Annual BioConnect Investor Conference?

Connect Biopharma will present on May 19, 2026 at 9:30 a.m. ET. Company management will participate in a fireside chat, offering investors an opportunity to hear updates on its inflammatory disease programs.

How can investors access the Connect Biopharma (CNTB) webcast for the May 19, 2026 BioConnect conference?

Investors can access the live webcast via the Investors section of the Connect Biopharma website. According to the company, the link will be available at investors.connectbiopharma.com ahead of the fireside chat.

Will a replay of Connect Biopharma's (CNTB) BioConnect 2026 presentation be available?

Yes, a replay of the Connect Biopharma presentation will be available on the company website. According to Connect Biopharma, the archived webcast will remain accessible for approximately 90 days after the conference.

What is the focus of Connect Biopharma (CNTB) for investors attending the H.C. Wainwright BioConnect conference?

Connect Biopharma is a clinical-stage biopharmaceutical company targeting inflammatory diseases. During the May 19, 2026 fireside chat, management is expected to discuss its development approach and pipeline focus for treating inflammatory conditions.

Where is Connect Biopharma (CNTB) headquartered and how is that relevant to the 2026 BioConnect conference?

Connect Biopharma is based in San Diego and focuses on inflammatory disease treatments. The company will join the New York-based H.C. Wainwright BioConnect conference virtually, offering global investors online access through a live webcast and replay.